Narcan Now Available Over the Counter to Reverse Opioid Overdoses

Safety
Published

Narcan, the trade name for Naloxone HCl Nasal Spray, was approved for over-the-counter (OTC) nonprescription use by the U.S. Food and Drug Administration in March, becoming the first naloxone product approved for use without a prescription. Naloxone is a medication that rapidly reverses the effects of opioid overdose and is the standard treatment for opioid overdose.

Emergent BioSolutions has announced that shipments of its over the counter, original prescription strength NARCAN® Nasal Spray 4mg are now being delivered to leading pharmacies and grocery stores, as well as online retailers.

Drug overdose persists as a major public health issue in the United States, with more than 101,750 reported fatal overdoses occurring in the 12-month period ending in October 2022, primarily driven by synthetic opioids like illicit fentanyl. Construction workers account for nearly 23% of all opioid overdose deaths. Many of these happened on the job.

When someone is having an opioid overdose, the receptors in their brain get filled and overstimulated by opioids and when these receptors are full or are “maxed out,” your brain tells your body to slow down or even stop your breathing. Naloxone works to reverse this process. It works by binding with and blocking opioid receptors to rapidly reverse the effects of opioid overdose.

According to Emergent, last year, approximately every seven minutes one life was lost due to an opioid overdose, and today it is the leading cause of accidental death in the United States. The average response time for emergency services to arrive is approximately 10 minutes.

Having NARCAN® Nasal Spray in a first-aid kit on a job site, or carrying it on the go in case of an opioid emergency, can make a difference and help reverse the effects of opioids while waiting for emergency personnel to arrive.

The manufacturer’s suggested retail price of NARCAN® Nasal Spray is $44.99 per two-dose carton, roughly $22.50 per dose.

Learn more about Naloxone. NAHB also has resources to address the opioid crisis in construction.

Subscribe to NAHBNow

Log in or create account to subscribe to notifications of new posts.

Log in to subscribe

Latest from NAHBNow

Economics | Housing Affordability

Feb 24, 2026

Falling Mortgage Rates Make Homeownership Possible for Millions of Households

The average interest rate on a 30-year fixed-rate mortgage fell to around 6% last week, the lowest rate borrowers have seen in close to three years. Borrowers will not only enjoy lower monthly payments at that rate, but it also makes homeownership possible for millions more.

Material Costs

Feb 23, 2026

Supreme Court Strikes Down Trump’s Tariffs – But Uncertainty Persists

The Supreme Court on Feb. 20 ruled that President Trump’s attempts to use emergency powers under the International Emergency Economic Powers Act (IEEPA) was not valid. But Trump still has wide latitude in setting tariff policy and announced a new global tariff of 15%. American consumers and businesses are unsure how any new tariffs will affect them.

View all

Latest Economic News

Economics

Feb 24, 2026

Young Adult Headship Rates in 2024: Cyclical Slip or New Equilibrium?

Reversing the post-pandemic rebound, the headship rates among young adults (the share of the population heading their own households) declined in 2024, according to NAHB’s analysis of the American Community Survey (ACS) data.

Economics

Feb 23, 2026

A 25-Basis-Point Decline in the Mortgage Rate Prices-In 1.42 Million Households

Housing affordability remains a critical challenge nationwide, and mortgage rates continue to play a central role in shaping homebuying power. Although rates have declined from the recent peak of about 7.6% in 2023 to around 6.01% as of February 19,2026, they remain elevated relative to typical levels in the 2010s.

Economics

Feb 20, 2026

New Home Sales Close 2025 with Modest Gains

New home sales ended 2025 on a mixed but resilient note, signaling steady underlying demand despite ongoing affordability and supply constraints. The latest data released today (and delayed because of the government shutdown in fall of 2025) indicate that while month-to-month activity shows a small decline, sales remain stronger than a year ago, signaling that buyer interest in newly built homes has improved.